Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Hosts Cannabis Symposium for Brazilian Doctors at Offices in San Diego
SAN DIEGO, May 1, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil hosted a symposium on cannabidiol (CBD) at Medical Marijuana, Inc.'s offices in downtown San Diego on Monday, April 30.
Attendees had the opportunity to listen to presentations on CBD and its many health and wellness benefits by Medical Marijuana, Inc. CEO Dr. Stuart Titus, HempMeds® Brasil Vice President Caroline Heinz, HempMeds® Brasil Director of Medical Affairs Junior S. Gibelli, HempMeds® Vice President of Latin America Raul Elizalde and clinical researchers Dr. Carlos G. Aguirre-Velazquez and Dr. Luiz Fernando Fonseca.
"HempMeds has a well-recognized global presence and a part of maintaining that presence is to connect influential leaders from different countries to continue to learn about cannabis and CBD," said HempMeds® Brasil Vice President Caroline Heinz. "We're happy that these doctors were able to travel all the way from Brazil for our event."
HempMeds® Brasil was the first company authorized by ANVISA to import a CBD-based product into Brazil for those suffering from various specific medical conditions.
"Having recently traveled to Brazil, it is nice to have these prominent medical professionals visit our home offices and provide them with personal interaction with some of our key international leaders," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We will continue to host home-and-home symposiums like this to help spread our knowledge on this amazing supplement and help increase global access."
About HempMeds Brasil™
HempMeds Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil is working on additional approvals for multiple indications.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
View original content with multimedia:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-brasil-hosts-cannabis-symposium-for-brazilian-doctors-at-offices-in-san-diego-300639651.html
SOURCE Medical Marijuana, Inc.